NASDAQ:CING Cingulate (CING) Stock Price, News & Analysis $11.19 +0.19 (+1.73%) (As of 10:46 AM ET) Add Compare Share Share Today's Range$11.00▼$12.4050-Day Range$0.24▼$17.6952-Week Range$1.80▼$187.20Volume520,714 shsAverage Volume1.45 million shsMarket Capitalization$82.19 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Cingulate alerts: Email Address Cingulate MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside29.7% Downside$8.00 Price TargetShort InterestHealthy0.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 11 Articles This WeekInsider TradingSelling Shares$842 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.81 out of 5 starsMedical Sector631st out of 924 stocksBiotechnology Industry14th out of 25 stocks 1.2 Analyst's Opinion Consensus RatingCingulate has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCingulate has received no research coverage in the past 90 days.Read more about Cingulate's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.10% of the float of Cingulate has been sold short.Short Interest Ratio / Days to CoverCingulate has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cingulate has recently decreased by 95.83%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCingulate does not currently pay a dividend.Dividend GrowthCingulate does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CING. Previous Next 2.9 News and Social Media Coverage News SentimentCingulate has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Cingulate this week, compared to 3 articles on an average week.Search Interest32 people have searched for CING on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat Follows8 people have added Cingulate to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cingulate insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $842.00 in company stock.Percentage Held by Insiders17.71% of the stock of Cingulate is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cingulate's insider trading history. Previous Next N/A Earnings and Valuation Read more about Cingulate's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.You need to check out the full story right here. About Cingulate Stock (NASDAQ:CING)Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Read More CING Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CING Stock News HeadlinesAugust 18, 2024 | finance.yahoo.comCingulate Inc. (CING)August 17, 2024 | nz.finance.yahoo.comCingulate Inc. (CINGW) latest press releases & corporate news – Yahoo FinanceAugust 22, 2024 | DTI (Ad)Air Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.August 17, 2024 | bizjournals.comCingulate wins patent approval in Europe for ADHD treatmentAugust 17, 2024 | marketwatch.comCingulate's Market Value Balloons on European Patent for ADHD DrugAugust 17, 2024 | msn.comCingulate Shares Are Trading By More Than 200% Friday: What You Need To KnowAugust 15, 2024 | msn.comNasdaq Jumps Over 2%; Walmart Earnings Top ViewsAugust 15, 2024 | benzinga.comWhat's Going On With Cingulate Shares Today?August 22, 2024 | DTI (Ad)Air Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.August 15, 2024 | nz.finance.yahoo.comCingulate Inc. (CINGW) interactive stock chart – Yahoo FinanceAugust 15, 2024 | nz.finance.yahoo.comCingulate Inc. (CINGW) stock price, news, quote & history – Yahoo FinanceAugust 15, 2024 | markets.businessinsider.comWhy Cingulate Is Rising In Pre-market?August 15, 2024 | globenewswire.comCingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHDAugust 13, 2024 | markets.businessinsider.comCingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones AchievedAugust 13, 2024 | globenewswire.comCingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones AchievedAugust 13, 2024 | bizjournals.comCingulate avoids Nasdaq delisting with reverse stock splitAugust 9, 2024 | msn.com‘You are your brain’: UNLV study analyzes how we experience timeAugust 9, 2024 | msn.comStudy reveals ways in which 40Hz sensory stimulation may preserve brain's 'white matter'See More Headlines Receive CING Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today8/22/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CING CUSIPN/A CIK1862150 Webwww.cingulate.com Phone913-942-2300FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside-27.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,530,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-448.18% Debt Debt-to-Equity RatioN/A Current Ratio1.21 Quick Ratio1.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($5.88) per share Price / Book-1.87Miscellaneous Outstanding Shares7,345,000Free Float6,044,000Market Cap$80.80 million OptionableNot Optionable Beta-1.07 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Shane J. Schaffer Pharm.D. (Age 49)CEO & Chairman of the Board Comp: $491.96kDr. Laurie A. Myers M.B.A. (Age 67)Ph.D., Executive VP & COO Comp: $415.17kDr. Matthew N. Brams M.D. (Age 60)Executive VP & Chief Medical Officer Comp: $244.79kMs. Jennifer L. Callahan CPA (Age 53)Senior VP, CFO & Secretary Dr. Raul R. Silva M.D. (Age 66)Executive VP & Chief Science Officer Thomas DaltonVice President of Investor & Public RelationsMore ExecutivesKey CompetitorsWVS FinancialNASDAQ:WVFCTrinity BiotechNASDAQ:TRIBOcugenNASDAQ:OCGNenGeneNASDAQ:ENGNGreenwich LifeSciencesNASDAQ:GLSIView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 490,000 shares on 8/15/2024Ownership: 6.671%Laurie MyersSold 202 sharesTotal: $842.34 ($4.17/share)Jennifer L CallahanBought 55 shares on 3/15/2024Total: $1,490.50 ($27.10/share)Jennifer L CallahanBought 250 shares on 9/15/2023Total: $3,350.00 ($13.40/share)View All Insider TransactionsView All Institutional Transactions CING Stock Analysis - Frequently Asked Questions How have CING shares performed this year? Cingulate's stock was trading at $7.65 on January 1st, 2024. Since then, CING shares have increased by 48.8% and is now trading at $11.38. View the best growth stocks for 2024 here. How were Cingulate's earnings last quarter? Cingulate Inc. (NASDAQ:CING) released its quarterly earnings data on Tuesday, August, 13th. The company reported ($5.47) EPS for the quarter, topping the consensus estimate of ($5.64) by $0.17. When did Cingulate's stock split? Shares of Cingulate reverse split on the morning of Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cingulate IPO? Cingulate (CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at $6.00-$8.00 per share. Who are Cingulate's major shareholders? Top institutional shareholders of Cingulate include Armistice Capital LLC (6.67%). Insiders that own company stock include Peter J Werth, Gregg Wm Givens, Jennifer L Callahan, Shane J Schaffer, Craig S Gilgallon, Curtis Medeiros, Horn Louis G Van and Laurie Myers. View institutional ownership trends. How do I buy shares of Cingulate? Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CING) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
